Recently, the "Expert Consensus on Vaccination of Rheumatic Immune Disease Patients in China (2023 Edition)" led by Lu Liangjing, chief physician of the Department of Rheumatology of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and Sun Xiaodong, deputy director of the Shanghai Municipal Center for Disease Control and Prevention, was officially published in the Chinese Journal of Preventive Medicine. It is reported that this is the first expert consensus on the vaccination of people with special immune status in China.
Rheumatological disease is a chronic disease with a complex disease spectrum. Infection is one of the most common comorbidities and major causes of death in patients with rheumatic diseases, which greatly affects the prognosis and quality of life of patients. Vaccination is one of the important means to prevent infection, however, there is still a lack of unified standards and norms for the vaccination of patients with rheumatic immune diseases.
In order to solve this imminent problem, the Standardized Management and Practice Branch of Immunization Planning of the China Vaccine Industry Association organized clinical experts, disease control experts and epidemiologists to formulate this consensus after many discussions and revisions based on existing clinical data, referring to similar international guidelines and consensus, and combining with the practical experience of domestic vaccination, so as to ensure its scientificity and practicability. The expert consensus included 8 commonly used vaccines, including influenza vaccine, pneumococcal vaccine, novel coronavirus vaccine, herpes zoster vaccine, human papillomavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, and rabies virus vaccine, and recommended the vaccination population, recommended vaccine type, vaccination timing, immunization regimen and drug adjustment.
The release of this expert consensus will provide actionable technical guidelines for vaccinators and rheumatologists, promote the standardized vaccination and infection prevention and control of rheumatic immune disease patients in China, and is expected to improve the quality of life and disease prognosis of rheumatic immune patients.
One of the consensus leaders.
1. Lu Liangjing, chief physician of the Department of Rheumatology of Renji Hospital, said that the release of the consensus is only a starting point, and the working group will continue to pay attention to the latest international research results and clinical evidence, and constantly update and improve the vaccination recommendations to better serve the majority of patients.
Li Jia, deputy chief physician of the Department of Rheumatology of Renji Hospital, and Guo Xiang, director of the Department of Vaccine Clinical Trial and Post-marketing Evaluation of the Institute of Immunization Program of Shanghai Center for Disease Control and Prevention, are the main experts of the consensus, and Li Ting, deputy chief physician of the Department of Rheumatology of Renji Hospital, is the participating expert.
*: China Youth Daily client.